Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors

International Journal of Neuropsychopharmacology

Volumn 11, Issue 5, 2008, Pages 685-699

  Cooper Kazaz, Rena ^a   Lerer, Bernard ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Acceleration; Augmentation; Enhancement; Major depressive disorder; Resistant depression; Specific serotonin reuptake inhibitors; Triiodothyronine

Indexed keywords

AMFEBUTAMONE; BUSPIRONE; CITALOPRAM; FLUOXETINE; LIOTHYRONINE; LITHIUM; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THYROTROPIN; VENLAFAXINE;

ADD ON THERAPY; AGITATION; ANXIETY; CLINICAL TRIAL; DIAPHORESIS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HEADACHE; HEART PALPITATION; HORMONAL THERAPY; HUMAN; MAJOR DEPRESSION; MEDLINE; MYALGIA; NERVOUSNESS; OUTCOME ASSESSMENT; PHOTOPHOBIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SWEATING; SYSTEMATIC REVIEW; THYROTROPIN BLOOD LEVEL; TREMOR; UNSPECIFIED SIDE EFFECT; VIVID DREAM; XEROSTOMIA;

ADULT; AGED; DEPRESSIVE DISORDER, MAJOR; DRUG EVALUATION; DRUG SYNERGISM; FEMALE; HUMANS; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; PUBMED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; TRIIODOTHYRONINE;

EID: 46449102084     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145707008206     Document Type: Review

References (63)

1. Abraham G, Milev R, Lawson JS (2006). T3 augmentation of SSRI resistant depression. Journal of Affective Disorder 91, 211-215.
2. Afflelou S, Auriacombe M, Cazenave M, Chartres JP, Tignol J (1997). Administration of high dose levothyroxine in treatment of rapid cycling bipolar disorders. Review of the literature and initial therapeutic application apropos of 6 cases. Encephale 23, 209-217 (French).
3. Agid O, Lerer B (2003). Algorithm based treatment of major depression in an outpatient clinic: clinical correlates of response to specific serotonin reuptake inhibitor and tiiodothyronine augmentation. International Journal of Neuropsychopharmacology 6, 41-49.
4. Altshuler LL, Bauer M, Frye MA, Gitlin MJ, Mintz J, Szuba MP, Leight KL, Whybrow PC (2001). Does thyroid supplementation accelerate tricyclic antidepressant response? a review and meta-analysis of the literature. American Journal of Psychiatry 158, 1617-1622.
5. APA (2000). Practice guidelines for the treatment of patients with Major Depressive Disorder (revision). American Journal of Psychiatry 157 (Suppl. 4), 1-45.
6. Appelhof BC, Brouwer JP, Van Dyck R, Fliers E, Hoogendijk WJG, Huyser J, Schene AH, Tijssen JGP, Wiersinga WM (2004). Triiodothyronine addition to paroxetine in the treatment of major depressive disorder. Journal of Clinical Endocrinology and Metabolism 89, 6271-6276.
7. Appelhof BC, Fliers E, Wekking EM, Schene AH, Huyser J, Tijssen JG, Endert E, van Weert HC, Wiersinga WM (2005). Combined therapy with levothyroxine and liothyronine in two ratios, compared with levothyroxine monotherapy in primary hypothyroidism: a double blind, randomized, controlled clinical trial. Journal of Clinical Endocrinology and Metabolism 90, 2666-2674.
8. Aronson R, Offman HJ, Joffe RT, Naylor CD (1996). Triiodothyronin augmentation in the treatment of refractory depression. A meta-analysis. Archives of General Psychiatry 53, 842-848.
9. Bauer MS, Whybrow PC (1990). Rapid cycling bipolar affective disorder. II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study. Archives of General Psychiatry 47, 435-440.
10. Bauer M, Hellweg R, Graf KJ, Baumgartener A (1998). Treatment of refractory depression with high-dose thyroxine. Neuropsychopharmacology 18, 444-455.
11. Bauer M, Whybrow PC, Angst J, Versiani M, Moller HJ (2002a). World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorder, part 1: acute and continuation treatment of Major Depressive Disorder. World Journal of Biological Psychiatry 3, 5-43.
12. Bauer M, Berghofer A, Bschor T, Baumgartener A, Keisslinger U, Hellweg R, Adli M, Baethge C, Muller-Oerlinghausen B (2002b). Supraphysiological doses of L-thyroxine in the maintenance treatment of prophylaxix-resistant affective disorders. Neuropsychopharmacology 27, 620-628.
13. Berlin I, Payan C, Corruble E, Puech AJ (1999). Serum thyroid-stimulating hormone concentration as an index of severity of major depression. International Journal of Neuropsychopharmacology 2, 105-110.
14. Blier P, de Montigny C (1994). Current advances and trends in the treatment of depression. Trends in Pharmacological Sciences 15, 220-226.
15. Brouwer JP, Appelhof BC, Hoogendijk WJ, Huyser J, Endert E, Zuketto C, Schene AH, Tijssen JG, Van Dyck R, Wiersinga WM, Fliers E (2005). Thyroid and adrenal axis in major depression: a controlled study in outpatients. European Journal of Endocrinology 152, 185-191.
16. Buneviĉius R, Kažanaviĉius G, Ž alinkeviĉius R, Prange AJ (1999). Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. New England Journal of Medicine 340, 424-429.
17. Clyde PW, Harari AE, Getka EJ, Shakir KM (2003). Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial. Journal of the American Medical Association 290, 2952-2958.
18. Cooper-Kazaz R, Apter JT, Cohen R, Karagichev L, Moussa SM, Grouper D, Drori T, Newman ME, Sackeim HA, Glaser B, Lerer B (2007). Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial. Archives of General Psychiatry 64, 679-688.
19. Corruble E, Berlin I, Lemoine A, Hardy P (2004). Should major depression with 'high normal' thyroid-stimulating hormone be treated preferentially with tricyclics? Neuropsychobiology 50, 144-146.
20. Duval F, Mokrani MC, Crocq MA, Jautz M, Bailey P, Diep TS, Macher JP (1996). Effects of antidepressant medication on morning and evening thyroid function tests during a major depressive episode. Archives of General Psychiatry 53, 833-840.
21. Engum A, Bjoro T, Mykletun A, Dahl AA (2002). An association between depression, anxiety and thyroid function- a clinical fact or an artifact? Acta Psychiatrica Scandinavica 106, 27-34.
22. Engum A, Bjoro T, Mykletun A, Dahl AA (2005). Thyroid autoimmunity, depression and anxiety: are there any connections? An epidemiological study of a large population. Journal of Psychosomomatic Research 59, 263-268.
23. Feldmesser-Reiss EE (1958). The application of triiodothyronine in the treatment of mental disorders. Journal of Nervous and Mental Disease 127, 540-546.
24. Flach FF, Celian CI, Rawson RW (1958). Treatment of psychiatric disorders with triiodothyronine. American Journal of Psychiatry 114, 841-842.
25. Fountoulakis KN, Iacovides A, Grammaticos P, St Kaprinis G, Bech P (2004). Thyroid function in clinical subtypes of major depression: An exploratory study. BMC Psychiatry 4, 1-9.
26. Fraser SA, Kroenke K, Callahan CM, Hui SL, Williams JW, Unutzer J (2004). Low yield of thyroid-stimulating hormone testing in elderly patients with depression. General Hospital Psychiatry 26, 302-309.
27. Frazer A (2001). Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical effects from in vitro potencies. Journal of Clinical Psychiatry 62 (Suppl. 12), 16-23.
28. Gambi F, De Berardis D, Sepede G, Campanella D, Galliani N, Carano A, La Rovere L, Salini G, Penna L, Cicconetti A, et al. (2005). Effects of mirtazapine on thyroid hormones in adult patients with major depression. International Journal of Immunopathology and Pharmacology 18, 737-744.
29. Gendall KA, Joyce PR, Mulder RT, Luty SE (2003). Thyroid indices and response to fluoxetine and nortriptyline in major depression. Journal of Psychopharmacology 17, 431-437.
30. Grabe HJ, Volzke H, Ludemann J, Wolff B, Schwahn C, John U, Meng W, Freyberger HJ (2005). Mental and physical complaints in thyroid disorders in the general population. Acta Psychiatrica Scandinavica 112, 286-293.
31. Grozinsky-Glasberg S, Fraser A, Nahshoni E, Weizman A, Leibovici L (2006). Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials. Journal of Clinical Endocrinology and Metabolism 91, 2592-2599.
32. Gulseren S, Gulseren L, Hekimsoy Z, Cetinay P, Ozen C, Tokatlioglu B (2006). Depression, anxiety, health-related quality of life, and disability inpatients with overt and subclinical thyroid dysfunction. Archives of Medical Research 37, 133-139.
33. Hatterer JA, Herbert J, Hidaka C, Roose SP, Gorman JM (1993). CSF transthyretin in patients with depression. American Journal of Psychiatry 150, 813-815.
34. Iosifescu DV, Howarth S, Alpert JE, Nierenberg AA, Worthington JJ, Fava M (2001). T3 blood levels and treatment outcome in depression. International Journal of Psychiatry in Medicine 31, 367-373.
35. Iosifescu DV, Nierenberg AA, Mischoulon D, Perlis RH, Papakostas GI, Ryan JL, Alpert JE, Fava M (2005). An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. Journal of Clinical Psychiatry 66, 1038-1042.
36. Joffe RT, Singer W (1990). A comparison of triiodothyronine and thyroxine in potentiation of tricyclic antidepressants. Psychiatry Research 32, 241-251.
37. Joffe RT, Levitt AJ (1992). Major depression and subclinical (grade II) hypothyroidism. Psychoneuroendocrinology 17, 215-221.
38. Joffe RT (1999). Peripheral thyroid hormone levels in treatment resistant depression. Biological Psychiatry 45, 1053-1055.
39. Joffe RT, Sokolov STH, Levitt AJ (2006). Lithium and triiodothyronine augmentation of antidepressants. Canadian Journal of Psychiatry 51, 791-793.
40. Lojko D, Rybakowski JK (2007). L-thyroxine augmentation of serotonergic antidepressants in female patients with refractory depression. Journal of Affective Disorders 103, 253-256.
41. Kastin AJ, Ehrensing RH, Schalch DS, Andersen MS (1972). Improvement in mental depression with decreased thyrotropin response after administration of thyrotropin-releasing hormone. Lancet 2, 740-742.
42. Nierenberg AA, DeCecco BA (2001). Definitions of antidepressant treatment response, remission, nonresponse, partial response and other relevant outcomes: a focus on treatment-resistant depression. Journal of Clinical Psychiatry 62 (Suppl. 16), 5-9.
43. Nierenberg AA, Fava M, Trivedi MH, Wisniewski SR, Thase ME, McGrath PJ, Alpert JE, Warden D, Luther JF, Niederehe G, et al. (2006). A comparison of lithium and T3 augmentation following two failed medication treatments for depression: a STAR*D report. American Journal of Psychiatry 163, 1519-1530.
44. Owens MJ, Morgan WN, Plott SJ, Nemeroff CB (1997). Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. Journal of Pharmacology and Experimental Therapeutics 283, 1305-1322.
45. Pfeiffer H, Scherer J, Albus M (2004). High dose L-thyroxine in therapy refractory depression: case analysis and catamnesis as quality control [in German]. Nervenartz 75, 242-248.
46. Posternak M, Novak S, Stern R, Hennessey J, Joffe R, Prange A, Zimmerman M (2007). A Pilot effectiveness study: placebo-controlled trial of adjunctive L-triiodothyronine (T3) used to accelerate and potentiate the antidepressant response. International Journal of Neuropsychopharmacology 10, 1-11.
47. Prange AJ, Lara PP, Wilson IC, Alltop LB, Breese GR (1972). Effects of thyrotropin-releasing hormone in depression. Lancet 2, 999-1002.
48. Rao ML, Ruhrmann S, Retey B, Liappis N, Fuger J, Kraemer M, Kasper S, Moller HJ (1996). Low plasma thyroid indices of depressed patients are attenuated by antidepressant drugs and influence treatment outcome. Pharmacopsychiatry 29, 180-186.
49. Rihmer Z, Aksikal H (2006). Do antidepressants t(h)reat(en) depressives? Toward a clinically judicious formulation of the antidepressant-suicidality FDA advisory in light of declining national suicide statistics from many countries. Journal of Affective Disorders 94, 3-13.
50. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz B, et al. (2006a). STAR*D study team. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. American Journal of Psychiatry 163, 1905-1917.
51. Rush AJ, Kraemer HC, Sackeim HA, Fava M, Trivedi MH, Frank E, Ninan PT, Thase ME, Gelenberg AJ, Kupfer DJ, et al. (2006b). Report by the ACNP task force on response and remission in major depressive disorder. Neuropsychopharmacology 31, 1841-1853.
52. Sagud M, Pivac N, Muck-Seler D, Jakovlijevic M, Mihaljevic-Peles A, Korsic M (2002). Effects of sertraline treatment on plasma cortisol, prolactine and thyroid hormones in female depressed patients. Neuropsychobiology 45, 139-143.
53. Shi L, Thiebud P, McCombs JS (2004). The impact of unrecognized bipolar disorders for patients treated for depression with antidepressants in the fee-for-services California Medicaid (Medi-Cal) program. Journal of Affective Disorders 82, 373-383.
54. Siegmund W, Spieker K, Weike AI, Giessmann T, Modess C, Dabers T, Kirsch G, Sanger E, Engel G, Hamm AO, Nauck M, Meng W (2004) Replacement therapy with levothyroxine plus triiodothyronine (bioavailable molar ratio 14:1) is not superior to thyroxine alone to improve well-being and cognitive performance in hypothyroidism. Clinical Endocrinology 60, 750-757.
55. Shelton RC, Winn S, Ekhatore N, Loosen PT (1993). The effects of antidepressants on thyroid axis in depression. Biological Psychiatry 33, 120-126.
56. Sullivan GM, Hatterer JA, Herbert J, Chen X, Roose SP, Attia E, Mann JJ, Marangell LB, Goetz RR, Gorman JM (1999). Low levels of transthyretin in the CSF of depressed patients. American Journal of Psychiatry 156, 710-715.
57. Sullivan GM, Mann JJ, Oquendo MA, Lo ES, Cooper TB, Gorman JM (2006). Low cerebrospinal fluid transthyretin levels in depression: correlations with suicidal ideation and low serotonin function. Biological Pychiatry 60, 500-506.
58. Thase ME, Rush AJ (1997). When at first you don't succeed: sequential strategies for antidepressant non-responders. Journal of Clinical Psychiatry 58 (Suppl. 13), 23-29.
59. Thomsen AF, Kvist TK, Andersen PK, Kessing L (2005). Increased risk of developing affective disorder in patients with hypothyroidism: a register-based study. Thyroid 15, 700-707.
60. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, et al. (STAR*D study team) (2006). Evaluation of outcome with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. American Journal of Psychiatry 163, 5-7.
61. Ustun TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ (2004). Global burden of depressive disorders in the year 2000. British Journal of Psychiatry 184, 386-392.
62. Wekking EM, Appelhof BC, Fliers E, Schene AH, Huyser J, Tijssen JG, Wiersinga WM (2005). Cognitive functioning and well-being in euthyroid patients on thyroxine replacement therapy for primary hypothyroidism. European Journal of Endocrinology 153, 747-753.
63. Whybrow PC (1994). The therapeutic use of triiodothyronine and high dose thyroxine in psychiatric disorder. Acta Medica Austriaca 21, 47-52.